A03AA04 - Mebeverine |
Propably not porphyrinogenic |
PNP |
Rationale
Mebeverine is not listed as a CYP-inducer or inhibitor, and is not known to interfere with the CYP-metabolism of other drugs. There are no indications of porphyrinogenic effects connected with the pharmacodynamic properties of the drug.
Some preparations may include the laxative ispanhula, which also is classified PNP.
Chemical description
Mebeverine is the veratric acid ester of a substituted ethylamphetamine derivative.
Therapeutic characteristics
Mebeverine is an antispasmodic used in conditions such as irritable bowel syndrome. It is administered orally.
Metabolism and pharmakokinetics
Mebeverine is metabolised by hydrolysis to veratric acid and mebeverine alcohol. Mebeverine alcohol may go through further breakdown and conjugation before it is renally excreted.
Preclinical data
Moore and Hift claims porphyrinogenisity is shown in in vitro studies, but gives no references.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
- Scientific articles
- Elliott S, Burgess V. Investigative implications of the instability and metabolism of mebeverine. J Anal Toxicol. 2006 Mar;30(2):91-7. PMID 16620538. #1056
- Moore MR, Hift RJ. Drugs in the acute porphyrias - toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):89-94. PMID 9074793. #1057
- Drug reference publications
- Sweetman SC, editor. Martindale: The complete drug reference. Mebeverine. Pharmaceutical Press 2009. #1058
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Colofac MR. #1059
Similar drugs
© NAPOS 2024